You are here

Press Release Archive

- Talazoparib Significantly Extends Progression-Free Survival in Phase 3 EMBRACA Trial of Patients with Metastatic Breast Cancer

Pfizer Inc. (NYSE:PFE) today announced that the Phase 3 EMBRACA trial in patients with germline (inherited) BRCA1/2-positive (gBRCA+) locally advanced and/or metastatic breast cancer (MBC) demonstrated superior progression-free survival (PFS) in patients treated with talazoparib, compared to patients who received physician’s choice standard of care chemotherapy. Median PFS was 8.6 months (95% CI: 7.2, 9.3) for patients treated with talazoparib and 5.6 months (95% CI: 4.2, 6.7) for those treated with chemotherapy [HR: 0.54 (95% CI: 0.41, 0.71), p<0.0001].

- Pfizer Inc. Announces (i) Private Exchange Offer for its 6.500 per cent. Notes due 2038 Open to Certain Investors and Related Tender Offer Open to All Investors and (ii) Tender Offer for its 5.750 per cent. Notes due 2021 and Related Solicitation of Consents

Pfizer Inc. (NYSE:PFE) (“Pfizer”) today announced that it has commenced a private offer to exchange (the “Exchange Offer”) any and all of its outstanding £1,500,000,000 6.500 per cent. Notes due 2038 (the “Old Notes”) in exchange for newly issued debt securities of Pfizer (the “New Notes”), on the terms and subject to the conditions set forth in the Offering Memorandum dated December 7, 2017 (the “Offering Memorandum” and, together with the accompanying exchange offer notice of guaranteed delivery, the “Exchange Offer Documents”).

- Spark Therapeutics and Pfizer Announce Publication in The New England Journal of Medicine of Interim Data from Phase 1/2 Clinical Trial of Investigational Gene Therapy for Hemophilia B

Spark Therapeutics (NASDAQ:ONCE), a fully integrated gene therapy company dedicated to challenging the inevitability of genetic disease, and Pfizer Inc. (NYSE:PFE), today announced that The New England Journal of Medicine has published interim data as of July 25, 2017, from the Phase 1/2 clinical trial of SPK-9001, an investigational gene therapy for hemophilia B. 

- Updated Data from Phase 3 Trial of IBRANCE® (palbociclib) Plus Letrozole in ER+, HER2- Metastatic Breast Cancer Confirm Improvement in Progression-Free Survival

Pfizer Inc. (NYSE:PFE) today announced updated progression-free survival (PFS) results from the Phase 3 PALOMA-2 trial reinforcing the clinical benefit of IBRANCE® (palbociclib) combined with letrozole. 

- Bristol-Myers Squibb and Pfizer Alliance Urge People to ‘Tune in to AFib, Take Note of Stroke Risk’

The Bristol-Myers Squibb and Pfizer Alliance, the National Stroke Association and iHeartMedia today launched ‘Tune in to AFib, Take Note of Stroke Risk’ to educate the estimated nearly seven million Americans in 2017 living with atrial fibrillation (AFib) not caused by a heart valve problem about their increased risk of stroke. People with AFib are five times more likely to have a stroke than those who do not have the condition, and these strokes are more severe and more likely to be fatal than strokes not associated with AFib.

- Pfizer Unveils 2017 ASPIRE Oncology/Hematology Clinical Research Awards Winners; Grants Totaling More than $6M in 2017

Pfizer Inc. (NYSE:PFE) today announced the recipients of the expanded Advancing Science through Pfizer Investigator Research Exchange (ASPIRE) Oncology/Hematology Clinical Research Awards. Nine grants totaling more than $6 million (USD) in funding were awarded to investigators in the United States (U.S.) to support clinical research projects involving Pfizer medicines in both breast and hematologic cancers for 2017. This program started in 2015 in breast cancer and chronic myeloid leukemia.

- Pfizer Enters into Agreement to Develop and Commercialize CRESEMBA® (isavuconazole) in China and Asia Pacific Region

Pfizer and Basilea Pharmaceutica Ltd., an international biopharmaceutical company specializing in the research and development of anti-infective and oncological medicines, today announced they have entered into an agreement whereby Pfizer will be granted the exclusive development and commercialization rights in China and several countries in the Asia Pacific region to CRESEMBA (isavuconazole). CRESEMBA is a novel antifungal medicine for the treatment of adult patients with diagnosed invasive aspergillosis and mucormycosis1, two serious infections associated with significant morbidity and mortality among immunocompromised patients, such as those with advanced HIV and those with cancer.

- Merck KGaA, Darmstadt, Germany, and Pfizer Provide Update on Phase III JAVELIN Gastric 300 Study in Patients with Pre-Treated Advanced Gastric Cancer

Merck KGaA, Darmstadt, Germany, and Pfizer Inc. (NYSE: PFE) today announced that the Phase III JAVELIN Gastric 300 trial did not meet its primary endpoint of superior overall survival (OS) with single-agent avelumab* . . .

- Pfizer Receives FDA Approval for SUTENT® (sunitinib malate) as First and Only Adjuvant Treatment for Adult Patients at High Risk of Recurrent Renal Cell Carcinoma

Pfizer Inc. (NYSE:PFE) today announced that the U.S. Food and Drug Administration has approved a new indication expanding the use of SUTENT® . . . 

- Pfizer Names Albert Bourla Chief Operating Officer

Pfizer today announced that Albert Bourla has been named Chief Operating Officer effective January 1, 2018. 

- BMS-Pfizer Alliance To Unveil Real-World Data Analyses - Cost, Safety and Comparative Effectiveness Findings Associated with Oral Anticoagulants in Non-Valvular Atrial Fibrillation

Bristol-Myers Squibb Company and Pfizer Inc. plan to release real-world data analyses of outcomes associated with direct oral anticoagulants...

- Pfizer Sells Its 49% Equity Share in Hisun-Pfizer Pharmaceuticals

Pfizer Inc. (NYSE: PFE) and Zhejiang Hisun Pharmaceuticals (Hisun) today announced that Pfizer has sold  its  49% equity share in its joint venture . . .

- Spark Therapeutics and Pfizer Amend License Agreement for Investigational SPK-9001 in Hemophilia B

Spark Therapeutics (NASDAQ:ONCE) and Pfizer Inc. (NYSE:PFE) today announced they have entered into an amendment to their license agreement . . .

- Pfizer Reports Third-Quarter 2017 Results

Pfizer reported financial results for thirdquarter 2017 and narrowed certain 2017 financial guidance ranges.

- One Year Maintenance and Switching Data in Patients with Crohn’s Disease Support the Use of INFLECTRA®* (infliximab CT-P13) in IBD1

New data show that switching patients with Crohn’s disease (CD) to INFLECTRA (infliximab CT-P13) from REMICADE (infliximab) led to comparable efficacy, safety and tolerability to treatment with REMICADE over a 24 week period.

- New Ulcerative Colitis Data for XELJANZ® (tofacitinib) at Upcoming Gastroenterology Congresses

Pfizer Inc. (NYSE:PFE) announced today that a total of 10 abstracts on XELJANZ® (tofacitinib) in ulcerative colitis (UC) will be presented at the World Congress of Gastroenterology at the American College of Gastroenterology (WCOG at ACG2017) (October 13-18, Orlando, Florida) and the 25th United European Gastroenterology (UEG) Week (October 28–November 1, Barcelona, Spain).
“We are pleased to share this informative data with the gastroenterology community as it deepens our knowledge of tofacitinib in UC and the multi-faceted needs of patients living with the condition,” said Michael Corbo, Chief Development Officer, Inflammation & Immunology, Pfizer Global Product Development.

- Pfizer Presents Full Results from Phase 2 Study of Next-Generation Investigational ALK-Inhibitor Lorlatinib in ALK-Positive and ROS1-Positive Advanced Non-Small Cell Lung Cancer

Pfizer Inc. (NYSE:PFE) today announced full results from the Phase 2 clinical trial of the investigational, next-generation tyrosine kinase inhibitor . . .

- The Union for International Cancer Control and Pfizer award new round of grants totalling US$500,000 to organisations in 19 countries to address the needs of metastatic breast cancer patients worldwide

This Metastatic Breast Cancer Awareness Day, the Union for International Cancer Control (UICC) and Pfizer Oncology are proud . . .

- U.S. FDA Approves LYRICA® CR (pregabalin) Extended-Release Tablets CV

Pfizer Inc. (NYSE: PFE) announced today that the United States Food and Drug Administration (FDA) has approved . . .

- Pfizer Reviewing Strategic Alternatives for Consumer Healthcare Business

Pfizer Inc. today announced that it is reviewing strategic alternatives for its Consumer Healthcare business. A range of options will be considered . . .


Note: These press releases were issued in the United States and are intended as reference information for U.S. investors and journalists. The information contained in each press release was accurate at the time of issuance, and Pfizer assumes no responsibility for updating the information to reflect subsequent developments.


Stock Quote Disclaimer

20 minute delayed data provided by Comstock. Charts are provided by BigCharts and MarketWatch, Inc. Pfizer makes no claims concerning the accuracy of the information provided on these pages, and will not be held liable for any use of this information. Note: Historical and current stock price performance data is not necessarily indicative of future performance.


If you do not have Adobe® Reader, download it here. It is available without charge from Adobe®. This link is provided as a convenience. Pfizer is not responsible for the content of this linked page.